emax nonlinear regression model graphpad prism v. 5.01 (GraphPad Software Inc)
GraphPad Software Inc is a verified supplier 
90
Structured Review
GraphPad Software Inc
emax nonlinear regression model graphpad prism v. 5.01
Emax Nonlinear Regression Model Graphpad Prism V. 5.01, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/emax+nonlinear+regression+model+graphpad+prism+v%2E+5%2E01/emax+nonlinear+regression+model+graphpad+prism+v++5+01/pm24218541-73-32-31
Average 90 stars, based on 1 article reviews
Emax Nonlinear Regression Model Graphpad Prism V. 5.01, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/emax+nonlinear+regression+model+graphpad+prism+v%2E+5%2E01/emax+nonlinear+regression+model+graphpad+prism+v++5+01/pm24218541-73-32-31
Average 90 stars, based on 1 article reviews
emax nonlinear regression model graphpad prism v. 5.01 - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis. Article Snippet: A critical piece in the translation of preclinical studies to clinical trials is the determination of dosing regimens that allow maximum therapeutic benefit with minimum toxicity.. The preclinical pharmacokinetic (PK)/pharmacodynamic (PD) profile of tofacitinib, an oral Janus kinase (JAK) inhibitor, in a mouse collageninduced arthritis (mCIA) model was compared with clinical PK/PD data from patients with rheumatoid arthritis (RA).. Preclinical evaluations included targetmodulation and PK/PDmodeling based on continuous subcutaneous infusion or oral onceor twice-daily (BID) dosing paradigms in mice. |